Q-omics provides the consensus-scored MIR5684 profile across patient tissues and cancer cell-line models. MIR5684 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, MIR5684 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, MIR5684 RNA expression shows 7,070 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight TGCT, KIRC, and DLBC as cancer lineages where MIR5684 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5684 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5684 survival associations across molecular data types. MIR5684 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5684 RNA expression–survival associations across cancer types. High MIR5684 expression shows unfavorable associations in TGCT, UCEC, LUAD and PRAD, but favorable associations in PAAD and SKCM. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for MIR5684 RNA expression.
This table summarizes MIR5684 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5684. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5684 shows lower tumor expression in BLCA, THCA and UCEC and higher tumor expression in KIRC, COAD and STAD. The KIRC box plot shows higher MIR5684 RNA expression in tumor versus normal tissue (log2 FC = +0.181, t-test p = .010).
This table shows molecular features associated with MIR5684 in patient tissues and cancer cell lines. In patient samples, MIR5684 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
